Our in vivo and in vitro results confirmed that the effect of treatment with HIF-1α RNAi combined with ASP was more obvious on HCC angiogenesis than the effects of HIF-1α RNAi and ASP treatment and that this combined treatment significantly lowered the p-ERK and p-AKT levels but had little influence on the ERK and AKT levels. This evidence concerns the gene HIF1A and hepatocellular carcinoma.